Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Revenue (2023 - 2025)

Immunome's Revenue history spans 3 years, with the latest figure at $4.0 million for Q2 2025.

  • For Q2 2025, Revenue rose 69.84% year-over-year to $4.0 million; the TTM value through Dec 2025 reached $6.9 million, down 23.23%, while the annual FY2025 figure was $6.9 million, 23.23% down from the prior year.
  • Revenue reached $4.0 million in Q2 2025 per IMNM's latest filing, up from $2.9 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $4.3 million in Q2 2023 to a low of $1.0 million in Q1 2024.
  • Average Revenue over 3 years is $3.0 million, with a median of $2.9 million recorded in 2024.
  • Peak YoY movement for Revenue: plummeted 56.47% in 2024, then skyrocketed 184.35% in 2025.
  • A 3-year view of Revenue shows it stood at $3.8 million in 2023, then decreased by 28.44% to $2.7 million in 2024, then skyrocketed by 46.64% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Revenue are $4.0 million (Q2 2025), $2.9 million (Q1 2025), and $2.7 million (Q4 2024).